# European Journal of Nuclear Medicine and Molecular Imaging

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/european-journal-of-nuclear-medicine-and-molecular-imaging/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 1619-7070 |
| ISSNs | 1619-7070,1619-7089 |
| OpenAlex ID | https://openalex.org/S191349260 |
| Publisher | Springer Science+Business Media |

## Journal papers

Showing 12 of 48.

- [The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours](https://scholariq.org/papers/the-joint-iaea-eanm-and-snmmi-practical-guidance-on-peptide-receptor/)
- [68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0](https://scholariq.org/papers/68ga-psma-pet-ct-joint-eanm-and-snmmi-procedure-guideline-for-prostate-cancer/)
- [Comparison of \[68Ga\]Ga-DOTA-FAPI-04 and \[18F\] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer](https://scholariq.org/papers/comparison-of-68ga-ga-dota-fapi-04-and-18f-fdg-pet-ct-for-the-diagnosis-of/)
- [FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease](https://scholariq.org/papers/fdg-pet-changes-in-brain-glucose-metabolism-from-normal-cognition-to/)
- [Myocardial perfusion scintigraphy: the evidence](https://scholariq.org/papers/myocardial-perfusion-scintigraphy-the-evidence/)
- [Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors](https://scholariq.org/papers/long-term-tolerability-of-prrt-in-807-patients-with-neuroendocrine-tumours-the/)
- [Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors](https://scholariq.org/papers/long-term-evaluation-of-renal-toxicity-after-peptide-receptor-radionuclide/)
- [Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study](https://scholariq.org/papers/peptide-receptor-radionuclide-therapy-with-177lu-dotatate-the-ieo-phase-i-ii/)
- [PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0](https://scholariq.org/papers/psma-pet-ct-joint-eanm-procedure-guideline-snmmi-procedure-standard-for-prostate/)
- [EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)](https://scholariq.org/papers/eanm-procedure-guidelines-for-radionuclide-therapy-with-177lu-labelled-psma/)
- [E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET](https://scholariq.org/papers/e-psma-the-eanm-standardized-reporting-guidelines-v1-0-for-psma-pet/)
- [Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study](https://scholariq.org/papers/receptor-mediated-radionuclide-therapy-with-90y-dotatoc-in-association-with/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.